FDA Approved Products
4,491 products with lifecycle intelligence, competitive pressure scores, and patent timelines.
AUGMENTIN '400'
amoxicillin; clavulanate potassium
LOE Approaching
Pfizer
ORAL · FOR SUSPENSION
infections due to susceptible strains of designated microorganismsthe treatment of infections due to susceptible (ONLY β-lactamase–negative) isolates of Streptococcus species+4
1996
NDA30/100
AUGMENTIN '400'
amoxicillin; clavulanate potassium
LOE Approaching
Pfizer
ORAL · TABLET, CHEWABLE
infections due to susceptible strains of designated microorganismsthe treatment of infections due to susceptible (ONLY β-lactamase–negative) isolates of Streptococcus species+4
1996
NDA30/100
AUGMENTIN '500'
amoxicillin; clavulanate potassium
LOE Approaching
Pfizer
ORAL · TABLET
infections due to susceptible strains of designated microorganismsthe treatment of infections due to susceptible (ONLY β-lactamase–negative) isolates of Streptococcus species+4
1984
NDA30/100
AUGMENTIN '875'
amoxicillin and clavulanate potassium
LOE Approaching
Pfizer
ORAL · TABLET
the following infections in adultsskin structure infections Urinary tract infections Limitations of Use+12
1996
NDA30/100
AUGMENTIN ES-600
amoxicillin and clavulanate potassium
LOE Approaching
Pfizer
ORAL · FOR SUSPENSION
equal to 40 kg with: Recurrentpersistent acute otitis media due to S+8
2001
NDA30/100
AUGMENTIN XR
amoxicillin and clavulanate potassium
LOE Approaching
Pfizer
ORAL · TABLET, EXTENDED RELEASE
infections due to Sequal to 40 kg+11
2002
NDA30/100
AUREOMYCIN
chlortetracycline hydrochloride
LOE Approaching
Pfizer
OPHTHALMIC · OINTMENT
1950
NDA30/100
AVAGARD
chlorhexidine gluconate and alcohol
LOE Approaching
TOPICAL · SOLUTION
bacteria
2001
NDA30/100
AVAGE
tazarotene
LOE Approaching
Almirall
TOPICAL · CREAM
psoriasis
2000
NDA30/100
AVALIDE
irbesartan and hydrochlorothiazide
LOE Approaching
Sanofi
ORAL · TABLET
hypertensionheart failure+1
1997
NDA30/100
AVANDAMET
metformin hydrochloride; rosiglitazone maleate
LOE Approaching
ORAL · TABLET
type 2 diabetes mellitusnot already taking rosiglitazone+5
2002
NDA30/100
AVANDARYL
glimepiride; rosiglitazone maleate
LOE Approaching
ORAL · TABLET
type 2 diabetes mellitus ( )type 1 diabetes mellitus+1
2005
NDA30/100
AVANDIA
rosiglitazone maleate
LOE Approaching
ORAL · TABLET
type 2 diabetes mellitustype 1 diabetes mellitus
1999
NDA30/100
AVAPRO
irbesartan
LOE Approaching
Sanofi
ORAL · TABLET
hypertensionto lower blood pressure+4
1997
SMNDA30/100
AVC
sulfanilamide
LOE Approaching
VAGINAL · CREAM
1965
NDA30/100
AVELOX
moxifloxacin hydrochloride
LOE Approaching
Bayer
ORAL · TABLET
Administration ()Use In Specific Populations ()]+22
1999
NDA30/100
AVELOX
moxifloxacin hydrochloride
LOE Approaching
R-Pharm US
Oral · Tablet
Administration ()Use In Specific Populations ()]+22
2001
NDA30/100
AVELOX IN SODIUM CHLORIDE 0.8% IN PLASTIC CONTAINER
moxifloxacin hydrochloride
LOE Approaching
Bayer
INTRAVENOUS · SOLUTION
Haemophilus influenzaeMoraxella catarrhalis+23
2001
NDA30/100
AVENTYL
nortriptyline hydrochloride
LOE Approaching
Signatur Biosciences
ORAL · SOLUTION
depression
1964
NDA30/100
AVENTYL HYDROCHLORIDE
nortriptyline hydrochloride
LOE Approaching
Eli Lilly and Company
ORAL · CAPSULE
depression
1964
NDA30/100
AVINZA
morphine sulfate
LOE Approaching
Pfizer
ORAL · CAPSULE, EXTENDED RELEASE
2002
NDA30/100
AVITA
tretinoin
LOE Approaching
TOPICAL · GEL
1998
NDA30/100
AVITA
tretinoin
LOE Approaching
Viatris (2)
TOPICAL · CREAM
1997
NDA30/100
AVODART
dutasteride
LOE Approaching
Viatris (2)
ORAL · CAPSULE
symptomatic benign prostatic hyperplasia (BPH) in men with an enlarged prostate to: () • improve symptoms• reduce the risk of acute urinary retention+5
2001
NDA30/100